Notably, loss of expression of both FGFR2 isoforms (FGFR2b-/FGFR2c-) was found in 13 tumour samples (4 of these were excluded from outcome analyses) (Table 3) with loss of both FGFR2 isoforms also associated with progestin treatment failure. Here, FGFR2 is linked to neoplasm.